. 2018 Feb;43(2):85-120.

Betrixaban (Bevyxxa): A Direct-Acting Oral Anticoagulant Factor Xa Inhibitor

Jessica W Skelley et al. P T. 2018 Feb.

. 2018 Feb;43(2):85-120.

Abstract

Betrixaban (Bevyxxa): a direct-acting oral anti-coagulant factor Xa inhibitor.

Disclosure: The authors report no commercial or financial interests in regard to this article.

A comparative analysis of the safety profile of direct oral anticoagulants using the FDA adverse event reporting system.
DeLoughery EP, Shatzel JJ. DeLoughery EP, et al. Eur J Haematol. 2019 Jul;103(1):43-46. doi: 10.1111/ejh.13240. Epub 2019 May 6. Eur J Haematol. 2019. PMID: 31009121 Free PMC article.
Coagulation modifiers targeting SARS-CoV-2 main protease Mpro for COVID-19 treatment: an in silico approach.
Biembengut ÍV, de Souza TACB. Biembengut ÍV, et al. Mem Inst Oswaldo Cruz. 2020;115:e200179. doi: 10.1590/0074-02760200179. Epub 2020 Jun 1. Mem Inst Oswaldo Cruz. 2020. PMID: 32490889 Free PMC article.
Updates in Anticoagulation Therapy Monitoring.
McRae HL, Militello L, Refaai MA. McRae HL, et al. Biomedicines. 2021 Mar 6;9(3):262. doi: 10.3390/biomedicines9030262. Biomedicines. 2021. PMID: 33800804 Free PMC article. Review.
Safety analysis of apixaban versus warfarin in patients with advanced kidney disease.
Bowie M, Valencia V, Perez-Alvarez I, Tran MH. Bowie M, et al. J Thromb Thrombolysis. 2018 Aug;46(2):246-252. doi: 10.1007/s11239-018-1683-5. J Thromb Thrombolysis. 2018. PMID: 29846888 Review.
The Clinical Significance of Drug-Food Interactions of Direct Oral Anticoagulants.
Grześk G, Rogowicz D, Wołowiec Ł, Ratajczak A, Gilewski W, Chudzińska M, Sinkiewicz A, Banach J. Grześk G, et al. Int J Mol Sci. 2021 Aug 8;22(16):8531. doi: 10.3390/ijms22168531. Int J Mol Sci. 2021. PMID: 34445237 Free PMC article. Review.

1. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160(6):809–815. - PubMed
1. Heit JA, O’Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med. 2002;162(11):1245–1248. - PubMed
1. Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 suppl):e195S–e226S. - PMC - PubMed
1. Barbar S, Noventa F, Rossetto V, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost. 2010;8(11):2450–2457. - PubMed
1. MacLean S, Mulla S, Akl EA, et al. Patient values and preferences in decision making for antithrombotic therapy: a systematic review: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 suppl):e1S–e23S. - PMC - PubMed